EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

New England Journal of Medicine

Volumn 352, Issue 8, 2005, Pages 786-792

  Kobayashi, Susumu ^a   Boggon, Titus J ^a   Dayaram, Tajhal ^a   Jänne, Pasi A ^a,b   Kocher, Olivier ^a   Meyerson, Matthew ^a   Johnson, Bruce E ^a,b   Eck, Michael J ^a   Tenen, Daniel G ^a,d   Halmos, Balázs ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; METHIONINE; TAXANE DERIVATIVE; THREONINE; ANTINEOPLASTIC AGENT; DNA; QUINAZOLINE DERIVATIVE; RNA;

ADVANCED CANCER; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER RELAPSE; CANCER RESISTANCE; CASE REPORT; CLINICAL FEATURE; DNA SEQUENCE; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; TREATMENT OUTCOME; AUDIOVISUAL EQUIPMENT; BIOPSY; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; SEQUENCE ANALYSIS; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MALE; MODELS, STRUCTURAL; MOLECULAR STRUCTURE; NEOPLASM RECURRENCE, LOCAL; POINT MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, NEOPLASM; SEQUENCE ANALYSIS, DNA; SEQUENCE ANALYSIS, RNA;

EID: 13844317894     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa044238     Document Type: Article

References (24)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
3. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-91.
4. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
5. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 Trial). J Clin Oncol 2003;21:2237-46. [Erratum, J Clin Oncol 2004;22:4811.]
6. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 Trial). J Clin Oncol 2003;21:2237-46. [Erratum, J Clin Oncol 2004;22:4811.]
7. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
8. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47.
9. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-9.
10. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
11. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
12. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
13. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7.
14. Cho D, Kocher O, Tenen DG, et al. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4: mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer. J Clin Oncol 2005;23:235-7.
15. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265-72.
16. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 1998;19:1639-62.
17. Schuettelkopf AW, van Aalten DMF. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 2004;60:1355-63.
18. Discafani CM, Carroll ML, Floyd MB Jr, et al. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochem Pharmacol 1999;57:917-25.
19. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
20. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004;64:5913-9.
21. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-43.
22. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
23. Blencke S, Ullrich A, Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 2003;278:15435-40.
24. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-24.